DE602005001696D1 - 4-(sulfanylpyrimidin-4-ylmethyl)morpholin-derivate und verwandte verbindungen als gaba-rezeptorliganden zur behandlung von angst, depression und epilepsie - Google Patents

4-(sulfanylpyrimidin-4-ylmethyl)morpholin-derivate und verwandte verbindungen als gaba-rezeptorliganden zur behandlung von angst, depression und epilepsie

Info

Publication number
DE602005001696D1
DE602005001696D1 DE602005001696T DE602005001696T DE602005001696D1 DE 602005001696 D1 DE602005001696 D1 DE 602005001696D1 DE 602005001696 T DE602005001696 T DE 602005001696T DE 602005001696 T DE602005001696 T DE 602005001696T DE 602005001696 D1 DE602005001696 D1 DE 602005001696D1
Authority
DE
Germany
Prior art keywords
sup
sub
atom
epilepsy
anxiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005001696T
Other languages
English (en)
Other versions
DE602005001696T2 (de
Inventor
Pari Malherbe
Raffaello Masciadri
Eric Prinssen
Will Spooren
Andrew William Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE602005001696D1 publication Critical patent/DE602005001696D1/de
Application granted granted Critical
Publication of DE602005001696T2 publication Critical patent/DE602005001696T2/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE602005001696T 2004-03-02 2005-02-22 4-(sulfanylpyrimidin-4-ylmethyl)morpholin-derivate und verwandte verbindungen als gaba-rezeptorliganden zur behandlung von angst, depression und epilepsie Active DE602005001696T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04100830 2004-03-02
EP04100830 2004-03-02
PCT/EP2005/001814 WO2005094828A1 (en) 2004-03-02 2005-02-22 4- (sulfanyl-pyrimidin-4-ylmethyl) -morpholine derivatives and related compounds as gaba receptor ligands for the treatment of anxiety, depression and epilepsy

Publications (2)

Publication Number Publication Date
DE602005001696D1 true DE602005001696D1 (de) 2007-08-30
DE602005001696T2 DE602005001696T2 (de) 2008-04-10

Family

ID=34896109

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005001696T Active DE602005001696T2 (de) 2004-03-02 2005-02-22 4-(sulfanylpyrimidin-4-ylmethyl)morpholin-derivate und verwandte verbindungen als gaba-rezeptorliganden zur behandlung von angst, depression und epilepsie

Country Status (14)

Country Link
US (1) US7351700B2 (de)
EP (1) EP1725239B1 (de)
JP (1) JP4563447B2 (de)
KR (1) KR100802863B1 (de)
CN (1) CN1925859B (de)
AT (1) ATE367163T1 (de)
AU (1) AU2005229505B2 (de)
BR (1) BRPI0508310A (de)
CA (1) CA2557719A1 (de)
DE (1) DE602005001696T2 (de)
ES (1) ES2290885T3 (de)
PL (1) PL1725239T3 (de)
RU (1) RU2382033C2 (de)
WO (1) WO2005094828A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2354647C2 (ru) * 2007-06-28 2009-05-10 Общество С Ограниченной Ответственностью "Бионика" Новые соединения, обладающие функцией ингибиторов тромбина, и фармацевтические композиции на их основе
RU2353619C2 (ru) * 2007-06-28 2009-04-27 Общество С Ограниченной Ответственностью "Бионика" Новые соединения, обладающие функцией антикоагулянтов, фармацевтические композиции на их основе для лечения тромботических состояний и плазмозамещающий раствор для коррекции гиперкоагуляционных нарушений при гемодилюции
JP2010533158A (ja) * 2007-07-09 2010-10-21 アストラゼネカ アクチボラグ 化合物類−９４５
TW201623257A (zh) 2014-05-09 2016-07-01 奧利安公司 藥理活性之喹唑啉二酮衍生物
KR102269132B1 (ko) 2014-06-10 2021-06-25 삼성디스플레이 주식회사 반방향족성 화합물 및 이를 포함하는 유기 발광 소자
US10084141B2 (en) 2014-06-13 2018-09-25 Samsung Display Co., Ltd. Antiaromatic compound and organic light-emitting device including the same
HU231058B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt. Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok
TW202220992A (zh) 2020-08-05 2022-06-01 匈牙利商羅特格登公司 具藥理活性之經雜環取代的吡唑并〔１，５－ａ〕嘧啶衍生物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6313146B1 (en) * 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
CN1142817A (zh) * 1993-10-12 1997-02-12 杜邦麦克制药有限公司 1n-烷基-n-芳基嘧啶胺及其衍生物
AU2001234420A1 (en) 2000-02-03 2001-08-14 Eli Lilly And Company Potentiators of glutamate receptors
WO2002083651A2 (en) * 2001-04-11 2002-10-24 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
GB0209481D0 (en) 2002-04-24 2002-06-05 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
JP2007526266A (ja) 2007-09-13
JP4563447B2 (ja) 2010-10-13
DE602005001696T2 (de) 2008-04-10
KR20060116240A (ko) 2006-11-14
KR100802863B1 (ko) 2008-02-12
US20050197337A1 (en) 2005-09-08
EP1725239B1 (de) 2007-07-18
EP1725239A1 (de) 2006-11-29
RU2382033C2 (ru) 2010-02-20
BRPI0508310A (pt) 2007-07-24
PL1725239T3 (pl) 2007-12-31
WO2005094828A1 (en) 2005-10-13
AU2005229505A1 (en) 2005-10-13
RU2006134632A (ru) 2008-04-10
CA2557719A1 (en) 2005-10-13
ATE367163T1 (de) 2007-08-15
CN1925859B (zh) 2010-11-24
CN1925859A (zh) 2007-03-07
ES2290885T3 (es) 2008-02-16
US7351700B2 (en) 2008-04-01
AU2005229505B2 (en) 2010-07-15

Similar Documents

Publication Publication Date Title
DE602005001696D1 (de) 4-(sulfanylpyrimidin-4-ylmethyl)morpholin-derivate und verwandte verbindungen als gaba-rezeptorliganden zur behandlung von angst, depression und epilepsie
MX2015011313A (es) Compuestos perfluorados de 5,6-dihidro-4h-1,3-oxazin-2-amina como inhibidores de beta-secretasa y metodos de uso.
NZ590951A (en) Cyclic nucleotide phosphodiesterases PDE10 inhibitors for treating neurological disorders
WO2007054444A3 (en) 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives
JP2010538001A5 (de)
ATE451373T1 (de) N-aryl diazaspirozyklische verbindungen, deren verwendung und das verfahren zu ihren herstellung
DE69509886T2 (de) 5H-INDENO[1,2-b]PYRAZIN-2,3-DION-DERIVATE ANTAGONISTEN DER AMPA UND NMDA REZEPTOREN
MXPA06011194A (es) Tiadiazolidinonas como inhibidores de gsk-3.
MA31373B1 (fr) Composes amino-heterocycliques
EA201000332A1 (ru) 1,3-двузамещенные 4-фенил-1н-пиридин-2-оны
WO2012042539A3 (en) 3 -azabicyclo [3.1.0] hexane compounds useful for the treatment of cns disorders
JP2007500168A5 (de)
IL202236A0 (en) Prolinamide derivatives as nk3 antagonists
EP2187888A2 (de) Bicyclische amide zur verbesserung der glutaminergen synaptischen antworten
NO20092198L (no) Nye Triazindionderivater som GABA-B-reseptormodulatorer
IL198926A0 (en) Compounds with a combination of cannabinoid-cb1 antagonism and acetylcholinesterase inhibition
EP2242364A1 (de) Zubereitung und enantiomere trennung von 7-(3-pyridinyl)-1,7-diazaspiro[4.4]nonan und neue salzformen des racemats und der enantiomere
Choi et al. Facile synthesis and biological evaluation of 3, 3-diphenylpropanoyl piperazines as T-type calcium channel blockers
NO20082436L (no) Forbindelser med medisinske effekter grunnet interaksjonen med glukokortikoidreseptor
CH634576A5 (de) Verfahren zur herstellung von aminoalkylpyrrolbenzoxaazaalkanen.
DE69608891T2 (de) Tetraline mit einem phenylsubstituenten am aromatischen ring und ihre verwendung in der behandlung von epilepsie, schlaganfall und gehirn- oder rückenmarkstrauma
WO1995007905A1 (fr) Derive d'imidazolidinone et procede pour sa production
JP2008509925A (ja) 新規のセロトニンレセプターリガンドおよびそれらの使用
Linzaga et al. NMR and X-ray crystallographic studies of axial and equatorial 2-ethoxy-2-oxo-1, 4, 2-oxazaphosphinane
NL8204462A (nl) Benzylideenderivaten, de bereiding hiervan en de therapeutische toepassing.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition